A Phase Ia/Ib Study of HS-10516 to Investigate the Safety, Tolerance, Pharmacokinetic and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma
Latest Information Update: 29 Sep 2023
At a glance
- Drugs HS 10516 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 29 Sep 2023 New trial record